Osteopontin as a Marker in Multiple Myeloma
Author Information
Author(s): Sfiridaki Aikaterini, Miyakis Spiros, Pappa Constantina, Tsirakis George, Alegakis Athanasios, Kotsis Vasileios, Stathopoulos Efstathios, Alexandrakis Michael
Primary Institution: Blood Bank Center, Venizelion General Hospital Heraklion, Crete, Greece
Hypothesis
Osteopontin levels correlate with disease stage and grade in multiple myeloma patients.
Conclusion
Osteopontin is a useful biomarker for monitoring disease activity in multiple myeloma patients.
Supporting Evidence
- Osteopontin levels were significantly higher in patients with advanced stage or grade of myeloma disease.
- All patients with serum osteopontin levels >100 ng/ml had advanced stage (II or III) or high grade bone disease.
- Serum osteopontin levels significantly decreased after treatment.
- There was a positive correlation of osteopontin with bone turnover marker NTx and angiogenic markers VEGF and microvessel density.
Takeaway
Osteopontin is a protein that helps doctors understand how severe multiple myeloma is in patients. Higher levels mean more serious disease.
Methodology
Serum levels of osteopontin were measured in untreated multiple myeloma patients and compared with healthy controls.
Limitations
The applicability of findings in different patient populations awaits validation.
Participant Demographics
50 untreated multiple myeloma patients (23 males, median age 68) and 25 healthy age & sex-matched controls (median age 65).
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI 1.2-2.0
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website